Editor's Note The widespread adoption of GLP-1 weight-loss medications like Ozempic and Wegovy could put revenue at risk across multiple service lines, according to a March 11 article in Becker’s Hospital Review. As a result, hospitals and ambulatory surgery centers (ASCs) face critical questions about how to adapt. The article…

Read More

Editor's Note In this panel at the 2025 OR Business Management Conference, led by Bob Winandy, MSN, MBA, RN, CEO of Brightside Surgical; Janet Carlson, MSN, BSN, RN, NE-BC, FACHE, executive director of ASCs at Commonwealth Pain & Spine; and Geri Eaves, BSN, RN, CASC, CNOR, CEO and administrator, The…

Read More

Editor's Note A study presented at the 2024 Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) annual meeting has revealed a significant correlation between financial conflicts of interest and favorable research outcomes in robotic bariatric surgery, General Surgery News January 18 reports. The article noted this concerning trend: authors who…

Read More

Editor's Note Despite a rise in discussions about bariatric surgery, a retrospective study spanning two decades revealed persistent racial and gender disparities in which patients undergo the procedure. MedPage Today reported the news January 16. The analysis, involving 122,487 patients, showed that only 9.1% with class II obesity or higher…

Read More

Editor's Note A recent survey from Orlando Health highlights limited awareness of the link between bariatric surgery and improved fertility, with only half of respondents acknowledging its benefits. According to January 16 coverage in Contemporary OB/GYN, the findings underscore a broader knowledge gap among the US population regarding the role…

Read More

Editor's Note Bariatric surgery programs nationwide have reported a 20-25% decline in surgical volumes over the past year amid the rising use of glucagon-like peptide-1 (GLP-1) medications for obesity, OR Management News reported Dec 2. Although the connection between the decline and the popularity of the drugs cannot be definitively…

Read More

Editor's Note Combining newer weight loss drugs with bariatric surgery is the most cost-effective long-term strategy for treating obesity, according to research presented at the American College of Surgeons Clinical Congress 2024. Medical Xpress reported on the findings October 18. According to the article, researchers from Northwestern Medicine evaluated the…

Read More

Editor's Note Bariatric surgery significantly reduces the progression of chronic kidney disease (CKD) in patients with type 2 diabetes and obesity compared to those on GLP-1 diabetes medications, according to a study from Cleveland Clinic. Published in Annals of Surgery and detailed in a September 20 announcement from Cleveland Clinic,…

Read More

Editor's Note Findings to be presented at the American Heart Association's Hypertension Scientific Sessions 2024 suggest bariatric surgery may offer more effective long-term control of high blood pressure for people with obesity compared to medications and lifestyle changes, according to a September 5 report in News Medical. According to the…

Read More

Editor's Note For diabetic patients with obesity and chronic kidney disease (CKD), metabolic bariatric surgery could protect the kidneys better than therapy with glucagon-like peptide-1 receptor agonists (GLP-1RA), according to research published in the September issue of the Annals of Surgery. Conducted at a large US health system, the study…

Read More